<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Kaji, Ryuji</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">A2NTX an Effective Substitute for OnabotulinumtoxinA in Poststroke Spasticity</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-05-20 11:31:42</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-13</style></pages><abstract><style  face="normal" font="default" size="100%">An A2 subtype form of botulinum toxin, A2NTX, is an effective substitute for onabotulinumtoxinA and demonstrates significantly larger decreases in Modified Ashworth Scale ankle plantar extensor at 30 days after injection. Functional independence also significantly improves at 60 days, and there is less toxin spread into other areas of the body following A2NTX injection.</style></abstract><number><style face="normal" font="default" size="100%">9</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>